IL17A and myeloid sarcoma: Several analyses of our dataset indicated the association of systemic IL-17 with the evolution of new Gd-enhancing and FLAIR lesions on MRI suggesting that this cytokine and the Th17 pathway may be important in BBB disruption and initiating inflammation in the brain of patients with MS.